Charles Schwab Investment Management Inc. Acquires 17,149 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Charles Schwab Investment Management Inc. boosted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 5.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 328,161 shares of the company's stock after acquiring an additional 17,149 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.69% of Mirum Pharmaceuticals worth $12,798,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Rice Hall James & Associates LLC lifted its holdings in shares of Mirum Pharmaceuticals by 6.9% during the 2nd quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company's stock worth $7,854,000 after acquiring an additional 14,843 shares during the period. Candriam S.C.A. bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth about $17,384,000. Hennion & Walsh Asset Management Inc. boosted its position in Mirum Pharmaceuticals by 64.9% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company's stock valued at $3,582,000 after buying an additional 41,236 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Mirum Pharmaceuticals by 48.2% during the second quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company's stock worth $4,889,000 after buying an additional 46,506 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in shares of Mirum Pharmaceuticals by 791.7% in the 3rd quarter. GSA Capital Partners LLP now owns 57,985 shares of the company's stock worth $2,261,000 after acquiring an additional 51,482 shares in the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of research analyst reports. Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. HC Wainwright reiterated a "buy" rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners increased their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of "Buy" and an average price target of $57.73.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM traded down $1.36 during mid-day trading on Monday, hitting $43.31. The stock had a trading volume of 389,429 shares, compared to its average volume of 545,587. The company's 50 day simple moving average is $41.57 and its 200 day simple moving average is $38.19. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the previous year, the firm earned ($0.57) EPS. The firm's revenue was up 89.4% compared to the same quarter last year. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Jolanda Howe sold 2,500 shares of the firm's stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the transaction, the senior vice president now owns 2,426 shares in the company, valued at approximately $114,264.60. This trade represents a 50.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.87% of the company's stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.